Shots: The interim analysis of open-label P- IIIb ENSEMBLE study of Ocrevus (ocrelizumab) showed 85% of patients achieved no evidence of disease activity in early-stage RRMS, low annualized relapse rate, […]readmore
Tags : New Data
Shots: Roche divulges new data that demonstrate Ocrevus (ocrelizumab) is a highly effective treatment option for people with RRMS who experienced a suboptimal response to their prior DMT. In open-label […]readmore
Biotech
Clinical Trials
Genentech to Present New Data of Enspryng (satralizumab-mwge) for Neuromyelitis
Shots: Genentech reports the new data for Enspryng on reducing relapse severity in the treatment of neuromyelitis optical spectrum disorder (NMOSD), to be presented at MSVirtual2020. In a pos-thoc analysis, […]readmore
Shots: Sanofi Genzyme reports the new data from the company’s neurology portfolio, to be presented at MSVirtual2020. The company will highlight new data on tolebrutinib (SAR442168), supporting its potential in […]readmore
Shots: Lilly to present results from a long-term study that evaluated the efficacy of Olumiant (4mg, qd) in patients with mod. to sev. RA for 3yrs. of treatment. The study […]readmore
Shots: Biogen to present data from BENEFIT study results assessing etanercept in 533 patients with rheumatoid arthritis and axial spondyloarthritis. Additionally, it presents data from pooled analyses of etanercept, infliximab […]readmore